PreveCeutical Medical Inc.
PRVCF
$0.0145
-$0.0005-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.91% | -30.82% | -39.99% | -17.05% | -27.69% |
| Depreciation & Amortization | -27.45% | -20.65% | -12.05% | -2.70% | 218.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.83% | -27.67% | -36.05% | -14.55% | -25.47% |
| Operating Income | -13.83% | 27.67% | 36.05% | 14.55% | 25.47% |
| Income Before Tax | -158.04% | -13.45% | 14.13% | 19.14% | 78.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -158.04% | -13.45% | 14.13% | 19.14% | 78.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.04% | -13.45% | 14.13% | 19.14% | 78.36% |
| EBIT | -13.83% | 27.67% | 36.05% | 14.55% | 25.47% |
| EBITDA | -14.58% | 27.71% | 36.27% | 14.67% | 26.45% |
| EPS Basic | -216.67% | -13.33% | 16.67% | 22.73% | 82.35% |
| Normalized Basic EPS | -200.00% | -22.22% | 9.09% | 8.33% | 80.00% |
| EPS Diluted | -216.67% | -13.33% | 16.67% | 22.73% | 82.35% |
| Normalized Diluted EPS | -200.00% | -22.22% | 9.09% | 8.33% | 80.00% |
| Average Basic Shares Outstanding | 0.47% | 0.96% | 1.46% | 2.60% | 3.09% |
| Average Diluted Shares Outstanding | 0.47% | 0.96% | 1.46% | 2.60% | 3.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
